Canadian Cancer Trials Group Bulletins

Trial Management Group


Trial Activation

IND.228, A Phase II Study of Durvalumab and Tremelimumab in Patients with Advanced Rare Tumours, was centrally activated on October 19, 2016.

The primary objective of this trial is to evaluate the objective response rate of the combination of durvalumab and tremelimumab given by IV every 4 weeks for 4 cycles, followed by durvalumab alone in patients with rare tumours.

Secondary objectives are to evaluate the:
  • Tolerability and safety of durvalumab and tremelimumab combination; and,
  • Effect of durvalumab and tremelimumab combination including time-to-progression, progression-free survival, and response duration.

Qualified centres interested in participating should contact Joana Sederias at jsederias@ctg.queensu.ca.